BioSpace News Archive

Cosmos Holdings, Inc. provided a business update and reported financial results for the first quarter ended March 31, 2022.

Children’s Hospital Colorado (Children’s Colorado) is the first hospital in the world to implant the newly FDA-approved G-Armor Stent.

Verastem Oncology today announced that it has received the first “Therapeutic Accelerator Award” from the Pancreatic Cancer Network (PanCAN).

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® has participated in the industry-led cannabidiol (CBD) Safety Study and that its preliminary results, released this week, are overwhelmingly positive for the safety profile of CBD.

INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that David Moss, Chief Financial Officer will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June.

The public health care system is facing unprecedented demand with patients routinely waiting over 10 hours in an emergency department for care. In the covid era, primary care is becoming increasingly difficult to access with many doctors seeing patients virtually.

Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.

Alan Schwartz, Executive Vice-President of mdi Consultants, Inc., commented, “We look forward to assisting Halberd’s new technology through the FDA review process. mdi has 44 years of regulatory experience and has successfully guided over 4,000 devices/products through the FDA review process.”